Modus Therapeutics Holding AB (publ) (MODTX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's live report from Modus Therapeutics, where I have with me CEO John Ödh to comment on the development during the second quarter of 2025 and also give an insight into the outlook forward. Welcome John to start with. Thank you, Jonathan. Thank you to everyone who listens in. I thought for those who have not been with us here during all the times we have run a report commentary, I thought you could give a short description of Modus and what you do and where you are right now. Absolutely. Modus is a company that develops a defined asset, which is our own asset. It is called Ceviparin and is a modified heparin that has important use areas in difficult diseases where there are still great needs for treatment. We have been noted on Nasdaq First North since 2021. Våra primära terapiområden där vi utvecklas över Paris är njursvikt med anemi, svår malaria som då främst drabbar små barn och sepsis med tillhörande andra liknande tillstånd som endotoxemi och så vidare. Sådant som händer i samband med svår infektion kan man säga. And you released the report for Q2 this morning. The CEO word breathes optimism, I have to say, because you have still delivered on the goals that you have set, quite simply. Can you just briefly comment on the most important events that you see during the quarter and maybe especially what happened late or at the beginning of the period? Yes, you can say that at the beginning of the quarter, så var vi väldigt fokuserade på att få igång rekryteringstakten och arbeta inåt med den studie som vi håller på med i kronisk djursjukdom med anemi. Det vi såg sedan var hur det arbetet bar frukt mot slutet av det andra kvartalet. Det här var ett arbete som bedrevs redan under det första kvartalet. De viktigaste händelserna var att vi på Enligt tidpl...